[ad_1]
meIn a statement, the community executive informs the approval of this contract, which is already the third that the institution signs with pharmaceutical companies that are in advanced stages in the development of vaccines for the new coronavirus.
“Once the safety and efficacy of the vaccine against COVID-19-19 [da belga Janssen], the contract allows Member States to buy vaccines for 200 million people “, in addition to having the” possibility to buy additional vaccines for 200 million more people “, explains the European Commission.
In addition, European Union (EU) countries “may also decide to donate the vaccine to low- and middle-income countries or redirectto other European countries “.
Before the contract announced today, the Commission entered into similar agreements with AstraZeneca and with him Sanofi–GSK, having also ended with success exploratory negotiations with CureVac, a BioNTech-Pfizer and Moderna.
The possible vaccine for Janssen against COVID-19-19 is based on a technology that allowed the pharmaceutical company to manufacture a vaccine against Ebolarecently approved, and candidates against the tell, The RSV is he HIV.
“The Commission’s decision to support this vaccine is based on a strong scientific evaluation, the technology used, the company’s experience in the field of vaccine development and its production capacity to supply the entire EU,” says the Commission. European.
No end of September, Johnson & Johnson announced that it would begin testing for phase 3, the last stage of development of its vaccine against COVID-19-19, which is expected to include up to 60,000 volunteers in eight countries, including Brazil.
The vaccine, whose official name is Ad26.COV2.S, is being developed by the pharmaceutical company Janssen, which is part of the Johnson & Johnson group.
Johnson & Johnson, which is committed to distributing the vaccine for no profit, has already emphasized that it intends to increase its production capacity, hoping to be able to deliver 1 billion doses of the vaccine per year from the start.
In addition to Brazil, phase 3 of the tests will also cover Argentina, Chile, Colombia, Mexico, Peru, Africa the South and the United States.
Phases 1 and 2 of this possible vaccine produced from Janssen they started in July in the United States of America and Belgium.
A pandemic of COVID-19-19 has already caused more than one million fifty-one thousand deaths and more than 35.8 million cases of infection around the world, according to a report by the French agency AFP.
In Portugal, 2,040 people died out of 81,256 cases of infection confirmed, according to the most recent Direction-General health.
The disease is transmitted by a new coronavirus detected not end of December, in Wuhan, a city in central China.
Always be the first to know.
Follow the chosen site for the fourth consecutive year Consumer Choice.
Download our free app.
[ad_2]
